Study identifier:D9090C00008
ClinicalTrials.gov identifier:NCT06299826
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure
Chronic heart failure
Phase 2
No
AZD5462, Placebo
All
360
Interventional
18 Years - 85 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort A & B: AZD5462 low dose Participants will receive low dose of AZD5462 as OD tablets for 24 weeks. | Drug: AZD5462 Participants will receive low, medium & high doses of film-coated tablets of AZD5462 OD orally. |
Experimental: Cohort A & B: AZD5462 medium dose Participants will receive medium dose of AZD5462 as OD tablets for 24 weeks. | Drug: AZD5462 Participants will receive low, medium & high doses of film-coated tablets of AZD5462 OD orally. |
Experimental: Cohort A & B: AZD5462 high dose Participants will receive high dose of AZD5462 as OD tablets for 24 weeks. | Drug: AZD5462 Participants will receive low, medium & high doses of film-coated tablets of AZD5462 OD orally. |
Experimental: Cohort A & B: Placebo Participants will receive matching placebo OD tablets for 24 weeks. | Drug: Placebo Participants will receive matching doses of film-coated tablets of Placebo OD orally. |